Strategic partnerships Kashiv BioSciences has active and recent collaboration activity with Intas Pharmaceuticals and licensing/marketing agreements in multiple regions through Alvotech, signaling openness to co-development, licensing, and distribution deals that can be pursued for additional biosimilars and manufacturing partnerships.

Manufacturing scale The company is vertically integrated with existing manufacturing facilities in the US and expansion of manufacturing and R&D sites in India and Southern Asia, presenting opportunities for contract manufacturing, tech transfer, and capacity-backed supply for biosimilar portfolios.

Financial capacity Recent financing from Union Bank of India and a substantial funding base indicate liquidity to pursue partnerships, expansions, and collaborative trials, making them a viable candidate for co-investment or supply agreements in emerging markets.

Biosimilar portfolio With commercial and advanced clinical-stage assets and recent launches such as PEXEGRA and FILRA in Canada, Kashiv demonstrates active market entry capabilities that can align with regions seeking approved biosimilars and downstream commercialization partnerships.

Regional expansion Expansion into India and broader Asia, plus existing US operations, creates cross-border sales opportunities for distributors, regional market access partners, and regulatory-compliant supply chains to accelerate market penetration of biosimilars and related products.